資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34114
|
| 標題: | Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment |
| 作者: | Wu, Yi-Hui
Huang, Yu-Fang
Chen, Chien-Chin
Huang, Chia-Yen
Chou, Cheng-Yang |
| 貢獻者: | Chi Mei Med Ctr, Dept Med Res
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol
Chia Yi Christian Hosp, Dept Pathol, Ditmanson Med Fdn
Chia Nan Univ Pharm & Sci, Dept Cosmet Sci
Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol
Cathay Gen Hosp, Gynecol Canc Ctr, Dept Obstet & Gynecol
Fu Jen Catholic Univ, Sch Med |
| 關鍵字: | epithelial ovarian carcinoma
chemoresistance
PI3K inhibitor
Akt inhibitor
cisplatin
paclitaxel |
| 日期: | 2020 |
| 上傳時間: | 2022-11-18 11:24:28 (UTC+8) |
| 出版者: | Frontiers Media Sa |
| 摘要: | Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. Herein, we sought to determine the efficacy of phosphoinositide 3-kinase (PI3K)/Akt inhibition using three AZD compounds in a NOD-SCID xenograft mouse model and Akt regulation in a panel of eight ovarian cancer cell lines. Elevated Akt phosphorylation on Ser473 but not on Thr308 in cancerous tissues correlated with short progression-free survival (PFS), overall survival (OS), and death. AZD8835 and AZD8186 inhibited Akt phosphorylation while AZD5363 augmented its phosphorylation on Ser473. To add, all compounds inhibited the Akt downstream effectors 4E-BP1 and p70S6 kinase. AZD8835 and AZD5363 sensitized chemoresistant ovarian cancer cells to cisplatin and paclitaxel treatment. Only AZD5363 could inhibit COL11A1 mRNA and promoter activity, which are important factors in Akt regulation and chemoresistance in ovarian cancer. By using a mouse xenograft model, AZD8835 and AZD5363, but not AZD8186, caused a significant reduction in tumor formation. AZD compounds did not change the mRNA expression of BRCA1/BRCA in ovarian cancer cells, but AZD8835 inhibited BRCA1/BRCA2 mRNA expression and p-ERK protein expression in OVCAR-8 cells with the KRAS mutation. This study highlights the importance of PI3K/Akt in ovarian tumor progression and chemoresistance and the potential application of AZD compounds, especially AZD8835 and AZD5363, as therapeutic agents for the treatment of ovarian cancer. |
| 關聯: | Frontiers In Pharmacology, v.11, pp.16 |
| 顯示於類別: | [化妝品應用與管理系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.3389fphar.2020.00206.pdf | | 4105Kb | Adobe PDF | 160 | 檢視/開啟 | | index.html | | 0Kb | HTML | 366 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
